Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
JB111 is an experimental CNS-directed AAV9-mediated PPT1 gene therapy, which is curently being evaluated in preclinical studies for the treatment of Alzheimer’s Disease.
Lead Product(s): JB111
Therapeutic Area: Neurology Product Name: JB111
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024